Crossmark

Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma

Crossref DOI link: https://doi.org/10.1186/s12943-026-02587-9

Published Online: 2026-02-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Boudreault, Julien

Rahimirad, Shima

Wang, Ni

Yan, Gang

Lima, Leslie Chaltel

Poulet, Sophie

Dai, Meiou

Ali, Suhad

Lebrun, Jean-Jacques
License Information

Text and Data Mining valid from 2026-02-05

Version of Record valid from 2026-03-09
More Information

Article History

Received: 2 July 2025

Accepted: 21 January 2026

First Online: 5 February 2026

Declarations

:

: All animals were housed and handled in accordance with the approved guidelines of the Canadian Council on Animal Care (CCAC) “Guide to the Care and Use of Experimental Animals”. All experiments were performed in accordance with the approved McGill University Animal Care protocol (AUP # 7497 to JJL).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below